Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports.

Autor: Ewer MS; Department of Cardiology, Internal Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mewer@mdanderson.org., Herson J; The Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Cardio-oncology (London, England) [Cardiooncology] 2022 Jul 19; Vol. 8 (1), pp. 13. Date of Electronic Publication: 2022 Jul 19.
DOI: 10.1186/s40959-022-00139-w
Abstrakt: Reports of cardiac adverse events from oncology clinical trials often are at variance with reports derived from clinical observations or data-base reviews. These differences may lead to confusion, as different levels of risks abound in the literature, and the true cardiac risk of using some agents is uncertain. Additionally, such discrepancies may lead to the creation of over-cautious surveillance algorithms. Reasons for these reported differences are complex and often reflect subtleties in the criteria for individual patient evaluation. Both clinical trial data and real-world data have potential flaws that make reconciliation problematic. Importantly, however, both provide crucial information regarding the risk of adverse events. Major factors contribute to these differences including different tools used to diagnose events, and how those tools are interpreted. Additionally, differences in the populations of clinical trial participants and real-world populations play a crucial role. This paper looks at these differences and provides a perspective intended to help clinicians interpret reported variations in event rates derived from highly scrutinized clinical trials and broader real-world data.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: